Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22792
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJackson, James E-
dc.contributor.authorAnderson, Nigel J-
dc.contributor.authorWada, Morikatsu-
dc.contributor.authorSchneider, Michal-
dc.contributor.authorPoulsen, Michael-
dc.contributor.authorRolfo, Maureen-
dc.contributor.authorFahandej, Maziar-
dc.contributor.authorGan, Hui-
dc.contributor.authorJoon, Daryl Lim-
dc.contributor.authorKhoo, Vincent-
dc.date2020-02-28-
dc.date.accessioned2020-03-16T23:02:01Z-
dc.date.available2020-03-16T23:02:01Z-
dc.date.issued2020-06-
dc.identifier.citationTechnical innovations & patient support in radiation oncology 2020; 14: 1-10-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22792-
dc.description.abstractTo identify organs to which dose limitation using intensity modulated radiotherapy (IMRT) can potentially modify the incidence and duration of feeding tube use, during and immediately following therapy for head and neck cancer. One hundred and fourteen patients treated with definitive IMRT (± concurrent chemotherapy) head and neck mucosal cancers were included. Patients received a prophylactic feeding tube and followed up by a dietician for at least eight weeks post-radiotherapy. Salivary and swallowing organs were delineated for each patient. Tumour and dosimetric variables were recorded for all patients and analysed for incidence and duration of feeding tube use for at least 25% of dietary requirements. Multivariate analysis showed T-classification ≥3 and level II lymphadenopathy as independent significant predictors of incidence and duration of feeding tube use in oral cavity, pharyngeal and supraglottic primaries. Mean dose deposited in the cervical oesophagus over 36Gy further increased the incidence and duration of feeding tube use. Mean dose deposited in the base of tongue and superior pharyngeal constrictor muscles affected incidence and duration of feeding tube use, respectively. In patients treated with definitive IMRT, T-classification and Level II lymphadenopathy, combined with a mean cervical oesophagus dose over 36Gy can a stratify patients into eight distinct risk groups for using feeding tubes for at least 25% of their dietary requirements.-
dc.language.isoeng-
dc.subjectEnteral nutrition-
dc.subjectHead and neck neoplasms-
dc.subjectIntensity-modulated-
dc.subjectRadiation dosage-
dc.subjectRadiotherapy-
dc.titleClinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleTechnical innovations & patient support in radiation oncology-
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationFaculty of Health Sciences and Medicine, Bond University, Gold Coast, Australiaen
dc.identifier.affiliationDepartment of Clinical Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Chelsea, London, UKen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationIcon Cancer Centres, Gold Coast University Hospital, Queensland, Australiaen
dc.identifier.affiliationDepartment of Palliative Care, St Vincent's Hospital, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Herston, Queensland, Australiaen
dc.identifier.affiliationDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Sciences, Monash University, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine, Griffith University, Gold Coast, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1016/j.tipsro.2020.01.003-
dc.identifier.orcid0000-0002-4826-2339en
dc.identifier.orcid0000-0002-1947-9694en
dc.identifier.pubmedid32154393-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Sep 3, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.